Previous 10 | Next 10 |
Aptose Biosciences (APS CN) initiated with Overweight rating at Piper Sandler. Shares up 2% premarket in U.S. (NASDAQ: APTO ). More news on: Aptose Biosciences Inc., BioDelivery Sciences International, Inc., BiomX Inc., Healthcare stocks news, Stocks on the move, , Read mor...
SAN DIEGO and TORONTO, Jan. 07, 2020 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President...
Shares of Aptose Biosciences (NASDAQ: APTO) were jumping 14% higher as of 3:14 p.m. EST on Wednesday. The clinical-stage biotech announced on Tuesday that its public stock offering of more than 16 million shares would be priced at $4 per share. Aptose's decision to raise money through a sto...
The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) had a turbulent week, starting at 3,788.38 points on Monday’s (December 9) open and reaching a five day high of 3,808.32 points on Friday (December 13) as of 10:30 a.m. EST. However, as of 12:00 p.m. EST Friday, the index was sitting at ...
3 Penny Stocks Just Hit Fresh December Highs, Can They Head Higher? Investing in penny stocks can often be the most rewarding thing for traders and investors alike. The simple reason behind it is the fact that these cheap stocks can often generate enormous returns, quickly. Since penny stoc...
Shares of Aptose Biosciences (NASDAQ: APTO) are up 11.5% as of 3 p.m. EST on Wednesday. This nice gain followed a huge move for the biotech stock on Monday. There were two major catalysts for Aptose. First, the company presented promising preclinical data for experimental drug CG-806 at the ...
I’ve written before that I consider Aptose Biosciences ( APTO ) to be a “speculation worth considering” on the strength of its two-drug pipeline for hematology, and between Merck ’s ( MRK ) $2.7 billion bid for ArQule ( ARQL ) and encouraging early-stage data...
December 10, 2019 Palm Beach, FL –December 10, 2019 – Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat cancer in ...
Thinly traded micro cap Aptose Biosciences ( APTO +37.5% ) is up on a 27x surge in volume in reaction to preclinical data on pipeline candidate CG-806. The results were presented at ASH in Orlando. More news on: Aptose Biosciences Inc., Healthcare stocks news, Stocks on the move, R...
Gainers: Synthorx (NASDAQ: THOR ) +170% . More news on: Synthorx, Inc., ArQule, Inc., Forty Seven, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Aptose Biosciences Inc. Company Name:
APTO Stock Symbol:
NASDAQ Market:
Aptose Biosciences Inc. Website:
SAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat hematologic malignancies, t...
SAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies,...
TUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational Drugs in AML TUS Monotherapy and TUS+VEN Doublet Therapy Active in...